The mean lorazepam dose administered in the symptom-triggered group was significantly lower than in the fixed tapering dose group ( 9.5 versus 19.9 mg , P < 0.001 ) and for a significantly shorter duration of time ( 47.8 versus 146 h , P < 0.001 ) with more significant results for higher initial CIWA-Ar scores .